| Dr Duane L Wires, OD | |
|
107 S Main St, Ada, OH 45810-1240 | |
| (419) 634-2921 | |
| (419) 634-9858 |
| Full Name | Dr Duane L Wires |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 40 Years |
| Location | 107 S Main St, Ada, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427040633 | NPI | - | NPPES |
| 055775 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 3756 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eyes On Main, Llc | 6709950991 | 4 |
News Archive
Fever is an effective defence against disease, but new research suggests that not all animals use it when exposed to infection.
A single injection of a new treatment has reduced the activity of the gene responsible for Huntington's disease for several months in a trial in mice.
The Physicians Committee for Responsible Medicine has called for the Food and Drug Administration (FDA) to push for cheese manufacturers to place breast cancer warning labels on their products.
Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
› Verified 7 days ago
| Provider Name | Eyes On Main, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477735538 PECOS PAC ID: 6709950991 Enrollment ID: O20080806000448 |
News Archive
Fever is an effective defence against disease, but new research suggests that not all animals use it when exposed to infection.
A single injection of a new treatment has reduced the activity of the gene responsible for Huntington's disease for several months in a trial in mice.
The Physicians Committee for Responsible Medicine has called for the Food and Drug Administration (FDA) to push for cheese manufacturers to place breast cancer warning labels on their products.
Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
› Verified 7 days ago
| Provider Name | Village Vision Center, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1730378373 PECOS PAC ID: 6800943325 Enrollment ID: O20090420000362 |
News Archive
Fever is an effective defence against disease, but new research suggests that not all animals use it when exposed to infection.
A single injection of a new treatment has reduced the activity of the gene responsible for Huntington's disease for several months in a trial in mice.
The Physicians Committee for Responsible Medicine has called for the Food and Drug Administration (FDA) to push for cheese manufacturers to place breast cancer warning labels on their products.
Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Duane L Wires, OD 107 S Main St, Ada, OH 45810-1240 Ph: (419) 634-2921 | Dr Duane L Wires, OD 107 S Main St, Ada, OH 45810-1240 Ph: (419) 634-2921 |
News Archive
Fever is an effective defence against disease, but new research suggests that not all animals use it when exposed to infection.
A single injection of a new treatment has reduced the activity of the gene responsible for Huntington's disease for several months in a trial in mice.
The Physicians Committee for Responsible Medicine has called for the Food and Drug Administration (FDA) to push for cheese manufacturers to place breast cancer warning labels on their products.
Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
› Verified 7 days ago
Village Vision Center, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 107 S Main St, Ada, OH 45810 Phone: 419-634-2921 Fax: 419-634-9858 | |
Mrs. Liane Marie Wilt, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 107 S Main St, Ada, OH 45810 Phone: 419-634-2921 Fax: 419-634-9858 |